Targeted therapy for multiple myeloma: an overview on CD138-based strategies
Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1370854/full |
| _version_ | 1797217011741229056 |
|---|---|
| author | Federico Riccardi Carmela Tangredi Carmela Tangredi Michele Dal Bo Giuseppe Toffoli |
| author_facet | Federico Riccardi Carmela Tangredi Carmela Tangredi Michele Dal Bo Giuseppe Toffoli |
| author_sort | Federico Riccardi |
| collection | DOAJ |
| description | Multiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains incurable, and most patients suffer from relapsed/refractory disease with poor prognosis and survival. The robust results achieved by immunotherapy targeting MM-associated antigens CD38 and CD319 (also known as SLAMF7) have drawn attention to the development of new immune-based strategies and different innovative compounds in the treatment of MM, including new monoclonal antibodies, antibody-drug conjugates, recombinant proteins, synthetic peptides, and adaptive cellular therapies. In this context, Syndecan1 (CD138 or SDC1), a transmembrane heparan sulfate proteoglycan that is upregulated in malignant plasma cells, has gained increasing attention in the panorama of MM target antigens, since its key role in MM tumorigenesis, progression and aggressiveness has been largely reported. Here, our aim is to provide an overview of the most important aspects of MM disease and to investigate the molecular functions of CD138 in physiologic and malignant cell states. In addition, we will shed light on the CD138-based therapeutic approaches currently being tested in preclinical and/or clinical phases in MM and discuss their properties, mechanisms of action and clinical applications. |
| first_indexed | 2024-04-24T11:55:05Z |
| format | Article |
| id | doaj.art-09c3879f86594d148403da3e2b16f57b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T11:55:05Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-09c3879f86594d148403da3e2b16f57b2024-04-09T04:32:53ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13708541370854Targeted therapy for multiple myeloma: an overview on CD138-based strategiesFederico Riccardi0Carmela Tangredi1Carmela Tangredi2Michele Dal Bo3Giuseppe Toffoli4Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, ItalyExperimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, ItalyDepartment of Life Sciences, University of Trieste, Trieste, ItalyExperimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, ItalyExperimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano, ItalyMultiple myeloma (MM) is an incurable hematological disease characterized by the uncontrolled growth of plasma cells primarily in the bone marrow. Although its treatment consists of the administration of combined therapy regimens mainly based on immunomodulators and proteosome inhibitors, MM remains incurable, and most patients suffer from relapsed/refractory disease with poor prognosis and survival. The robust results achieved by immunotherapy targeting MM-associated antigens CD38 and CD319 (also known as SLAMF7) have drawn attention to the development of new immune-based strategies and different innovative compounds in the treatment of MM, including new monoclonal antibodies, antibody-drug conjugates, recombinant proteins, synthetic peptides, and adaptive cellular therapies. In this context, Syndecan1 (CD138 or SDC1), a transmembrane heparan sulfate proteoglycan that is upregulated in malignant plasma cells, has gained increasing attention in the panorama of MM target antigens, since its key role in MM tumorigenesis, progression and aggressiveness has been largely reported. Here, our aim is to provide an overview of the most important aspects of MM disease and to investigate the molecular functions of CD138 in physiologic and malignant cell states. In addition, we will shed light on the CD138-based therapeutic approaches currently being tested in preclinical and/or clinical phases in MM and discuss their properties, mechanisms of action and clinical applications.https://www.frontiersin.org/articles/10.3389/fonc.2024.1370854/fullmultiple myelomaCD138sheddingimmunotherapyanti-cancer peptides |
| spellingShingle | Federico Riccardi Carmela Tangredi Carmela Tangredi Michele Dal Bo Giuseppe Toffoli Targeted therapy for multiple myeloma: an overview on CD138-based strategies Frontiers in Oncology multiple myeloma CD138 shedding immunotherapy anti-cancer peptides |
| title | Targeted therapy for multiple myeloma: an overview on CD138-based strategies |
| title_full | Targeted therapy for multiple myeloma: an overview on CD138-based strategies |
| title_fullStr | Targeted therapy for multiple myeloma: an overview on CD138-based strategies |
| title_full_unstemmed | Targeted therapy for multiple myeloma: an overview on CD138-based strategies |
| title_short | Targeted therapy for multiple myeloma: an overview on CD138-based strategies |
| title_sort | targeted therapy for multiple myeloma an overview on cd138 based strategies |
| topic | multiple myeloma CD138 shedding immunotherapy anti-cancer peptides |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1370854/full |
| work_keys_str_mv | AT federicoriccardi targetedtherapyformultiplemyelomaanoverviewoncd138basedstrategies AT carmelatangredi targetedtherapyformultiplemyelomaanoverviewoncd138basedstrategies AT carmelatangredi targetedtherapyformultiplemyelomaanoverviewoncd138basedstrategies AT micheledalbo targetedtherapyformultiplemyelomaanoverviewoncd138basedstrategies AT giuseppetoffoli targetedtherapyformultiplemyelomaanoverviewoncd138basedstrategies |